Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Apr;3(4):326-335.
doi: 10.1016/j.oret.2019.01.004. Epub 2019 Jan 11.

Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4

Amitha Domalpally  1 , Traci E Clemons  2 , Susan B Bressler  3 , Ronald P Danis  4 , Michael Elman  5 , Judy E Kim  6 , David Brown  7 , Emily Y Chew  8
Affiliations
Multicenter Study

Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4

Amitha Domalpally et al. Ophthalmol Retina. 2019 Apr.

Abstract

Purpose: To characterize choroidal neovascular (CNV) lesions and the corresponding change in visual acuity (VA) in eyes that converted to neovascular age-related macular degeneration (AMD) in the Age-Related Eye Disease Study 2-HOme Monitoring of the Eye Study. (AREDS2-HOME Study).

Design: Cohort study.

Participants: A total of 1520 participants at risk of developing CNV were enrolled, each of whom contributed 1 or both study eye(s) that had a best-corrected VA letter score of ≥54 letters (Snellen equivalent 20/60) and ≥1 large (≥125 μm) macular druse in the absence of neovascular AMD or central geographic atrophy.

Methods: A multicenter clinical trial comparing standard care (SC) versus SC plus ForeseeHome (FH; Notal Vision, Manassas, VA) monitoring strategy in the detection of neovascular AMD. Fluorescein angiograms (FA) and OCT were evaluated by an independent reading center (RC) from the visit in which the ophthalmologist identified progression to CNV (n = 82 eyes).

Main outcome measures: Development of CNV on OCT, FA, or both.

Results: The RC confirmed CNV in 67 of 82 eyes (82%); lesions were confirmed in 42 of 70 eyes (60%) with FA, 59 of 72 eyes (82%) with OCT, and on both images in 34 of 67 eyes (51%). Among the FA-confirmed cases, the median lesion size was 0.82 disc area (DA); lesions were subfoveal in 40.5%, occult CNV composition was present in 54.8%, and associated hemorrhage in 50%. Median (interquartile range [IQR]) lesion size on FA was 0.23 (0.0-0.91) DA versus 0.70 (0.0-1.50) DA, P = 0.051) in the FH and SC eyes, respectively. Among the OCT-confirmed cases median (IQR) center point thickness was 209 (175-274) μm, retinal pigment epithelial lesion complex was present in 86.4%, and subretinal fluid (SRF) was present in 76.3%. The median change in VA from baseline was -4.0 letters and -10.0 letters in the FH and SC eyes (P = 0.008) confirmed as CNV at the RC.

Conclusions: Incident CNV lesions were more prevalent on OCT images than on FA; however, the use of both OCT and FA enhanced detection of incident lesions. Lesions were smaller and associated with less vision loss among eyes in the FH group.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure(s):

The author(s) have made the following disclosure(s): A.D.: Research support – University of Wisconsin.

T.E.C.: Research support – The Emmes Corporation.

S.B.: Employee –Johns Hopkins University; Grant support – Notal Vision Ltd, Boehringer-Ingelheim, Biophytis, Genentech, Mylan Inc, Novartis, and Bayer.

R.P.D.: Research support – University of Wisconsin.

M.E.: Consultant – Genentech; Research support – Genentech, Alcon/Novartis, Thrombogenics, Apellis Pharmaceuticals and Neurotech, YD Global Life Science.

J.E.K. Consultant – Notal Vision, Genentech, and Alimera Science; Research support – Notal Vision and Optos.

D.M.B.: Research support – Notal Vision, Genentech/Roche, Regeneron/Bayer, and Alcon/Novartis; Consultant – Notal Vision, Genentech/Roche, Regeneron/Bayer, and Alcon/Novartis.

Figures

Figure 1.
Figure 1.
Choroidal neovascular macular degeneration (CNV) visible on fluorescein angiogram (FA) and OCT. The top row shows early and late-phase FA images with the arrow depicting CNV. The bottom row shows an OCT image with CNV (arrow) and corresponding line scan on the color photograph.
Figure 2.
Figure 2.
Choroidal neovascular macular degeneration (CNV) on fluorescein angiogram (FA) only. Early and late-phase of FA showing CNV (arrow in top row). OCT in the corresponding area does not show any signs of CNV (bottom).
Figure 3.
Figure 3.
Choroidal neovascular macular degeneration (CNV) visible on OCT only. Early and late-phase fluorescein angiogram images (top row) show fluorescein staining and no evidence of CNV. OCT shows active CNV with subretinal fluid at corresponding line scan depicted on the color photograph.
See this image and copyright information in PMC

References

    1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984;102:1640–1642. - PubMed
    1. Varma R, Bressler NM, Doan QV, et al. Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States. Ophthalmology. 2015;122:982–989. - PubMed
    1. Lee AY, Lee CS, Butt T, et al. UK AMD EMR Users Group Report V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol. 2015;99:1045–1050. - PMC - PubMed
    1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431. - PubMed
    1. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009; 116:57–65.e55. - PubMed

Publication types